Levitra

Vardenafil, the active ingredient in Levitra, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a buccal formulation for oral use. It treats erectile dysfunction in adult males. GNH USA supplies Levitra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levitra belongs to the phosphodiesterase type 5 inhibitor class and is used to manage conditions affecting male sexual function.

Erectile dysfunction: improves the ability to achieve and maintain an erection when sexually stimulated. Male sexual dysfunction: supports erectile response in men with physiological causes. Psychogenic erectile dysfunction: aids erection when psychological factors are present.

Common Side Effects: - Headache: mild to moderate pain in the head. - Flushing: warmth and redness of the face or upper body. - Nasal congestion: blocked or runny nose. - Dyspepsia: indigestion or upset stomach. - Back pain: aching discomfort in the lower back. - Visual changes: blurred vision or color tint.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours. - Sudden vision loss: abrupt loss of vision in one or both eyes. - Sudden hearing loss: unexpected loss of hearing. - Severe hypotension: dangerous drop in blood pressure. - Cardiovascular events: chest pain, heart attack, or stroke. - Allergic reactions: rash, swelling, or difficulty breathing.

Before using Levitra, consider the following safety measures.

Cardiovascular assessment: ensure the patient can tolerate sexual activity. Nitrate use: avoid concurrent use with nitrates or nitric‑oxide donors. Alpha‑blocker caution: monitor blood pressure if combined with alpha‑blockers. Severe liver impairment: use only if benefits outweigh risks. Hypotension risk: do not use in patients with low blood pressure. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Levitra may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Nitrates: concurrent use can cause severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): may lead to dangerous blood‑pressure drops. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase vardenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may enhance blood‑pressure lowering effects. - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels.